Lev Pharmaceuticals' Drug Candidate for Hereditary Angioedema Focus of Broadcast News Story

Lev Pharmaceuticals' Drug Candidate for Hereditary Angioedema Focus of Broadcast News Story

NEW YORK, June 26 /PRNewswire-FirstCall/ -- Lev Pharmaceuticals, Inc. ("Lev") (BULLETIN BOARD: LEVP.OB) , a developer of therapeutics for inflammatory diseases, announced today that its drug candidate for the treatment of hereditary angioedema (HAE) was the focus of a news story that aired on the WB11 News at 10:00 pm (WPIX-TV New York) on June 21. The segment can be seen at http://wb11.empowereddoctor.com/.

During the segment, a clinical investigator at Mt. Sinai and a patient with HAE both spoke about Lev's C1-esterase inhibitor (C1-INH), which is in Phase III trials and has been used in Europe for over 30 years. Dr. Paula Busse, the principal investigator for Lev's study site at Mt. Sinai Medical Center in New York, noted that, if approved by the FDA, the treatment could have a "huge impact and [HAE] patients are very, very excited about it."

The segment, which could run on as many as 40 television stations throughout the country, was produced by Empowered Health News, a premium television health news service that creates news stories for news outlets throughout the US.

"We are gratified that the media is beginning to recognize that Lev's C1- INH treatment may play an important role in treating HAE and preventing the symptoms from appearing in severely affected patients," said Joshua D. Schein, Ph.D., CEO of Lev Pharmaceuticals.

About Lev Pharmaceuticals, Inc.

Lev is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. Lev's product candidates are based on C1-esterase inhibitor ("C1- INH"), a human plasma protein that mediates inflammation and is potentially applicable as a treatment for a range of medical indications. The Company initiated a Phase III clinical trial of its lead product candidate, C1-INH for the treatment of hereditary angioedema, in March 2005. Lev is also developing C1-INH for the treatment of acute myocardial infarction, or heart attack, and selective other diseases and disorders in which inflammation is known or believed to play an underlying role.

Legal notice to investors: Certain matters discussed in this news release are "forward-looking statements." These forward-looking statements, which apply only on the date of this release, generally can be identified by the use of forward-looking terminology such as "may," "will," "expects," "intends," "estimates," "anticipates," "believes," "continues" or words of similar import. Similarly, statements that describe Lev's future plans, objectives or goals are also forward-looking statements, which generally involve known and unknown risks, uncertainties and other facts that may cause the actual results, performance or achievements of Lev to be materially different from those expressed or implied by such forward-looking statements. Such factors may include the following: uncertainties associated with product development, the risk that Lev will not obtain approval to market its products, the risk that Lev's products will not gain market acceptance, the risks associated with dependence upon key personnel and the need for additional financing.

Source: Lev Pharmaceuticals, Inc.

CONTACT: Joshua D. Schein, Ph.D. of Lev Pharmaceuticals, Inc.,
+1-212-682-3096, jschein@levpharma.com; or Media, Jeff Siegel of Monarch
Communications, Inc., +1-516-569-4271, jeffs@monarchcomminc.com

-------
Profile: intent